AgenT-797

N/A

Report date: 2022/09/06 18:03:12

Base Information

Drug NameAgenT-797
Drug Alias NameAllogeneic iNKT therapy(Agenus)Allogeneic iNKT cell therapies(Agenus)Unmodified iNKT cell therapies(Agenus)AgenT-797
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Invariant natural killer T cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursRespiratory Distress Syndrome, Adult +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAutonomous Therapeutics IncMiNK Therapeutics IncMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaSolid tumoursRespiratory Distress Syndrome, Adult +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A